FLT3 and acute myeloid leukemia: ABT-869 given orally was effective in multiple in vivo human xenograft tumor growth models and showed in vivo mechanism-based targeting, including acute myeloid leukemia with FLT3 mutation (MV4–11), highly angiogenic fibrosarcoma (HT1080), small cell lung carcinoma (H526, known to express KIT), colon adenocarcinoma (DLD-1), epidermoid carcinoma (A431) and breast cancinoma (MX-1).